Biomarkers and therapy for cancer

A method of determining whether an individual has serous ovarian cancer or is at risk for developing serous ovarian cancer, comprising the step of determining that when the expression of one or more of Secreted phosphoprotein 1, Chemokine (C-X-C motif) ligand 9, Chemokine (C-X-C motif) ligand 10, CD72 antigen, Solute carrier family 15, member 3, CD84 antigen, Complement component 1qB, Plasminogen activator, urokinase, Lymphocyte antigen 86, Mucin 16 (CA125), Folate receptor 1, Solute carrier family 11, member 1, Solute carrier family 12, member 8, CD40 antigen, Immunoglobulin superfamily, member 9, Interleukin 10 receptor, alpha, Tumor necrosis factor receptor, member 12a, Apolipoprotein E, Toll-like receptor 7, Transmembrane protein 48, Interleukin 1 receptor, type II, Leukocyte-associated Ig-like receptor 1, Lymphocyte antigen 6 complex, locus E, A disintegrin and metallopeptidase domain 17, Pleiotrophin, CD83 antigen, Chemokine (C-C motif) ligand 8, Transmembrane channel-like gene family 6, Transmembrane protein 49, Endothelial cell-specific molecule 1, Anti-Mullerian hormone type 2 receptor, Midkine, Transmembrane protein 173, Tumor necrosis factor receptor, member 21, Complement factor B, or Secretory carrier membrane protein 5 is upregulated in a sample from the individual, the individual has serous ovarian cancer or is at risk for having serous ovarian cancer.

A method of treating cancer in an individual, comprising the step of delivering a therapeutically effective amount of YM155 and parthenolide to the individual.